Treatment with anti-TNF alpha protects against the neuropathy induced by the proteasome inhibitor bortezomib in a mouse model

Experimental Neurology

Volumn 253, Issue , 2014, Pages 165-173

  Alé, Albert ^a   Bruna, Jordi ^a   Morell, Marta ^a   van de Velde, Helgi ^b   Monbaliu, Johan ^b   Navarro, Xavier ^a   Udina, Esther ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Bortezomib; Chemotherapy induced peripheral neuropathy; Cytokines; Mice; Neuropathy; Proteasome inhibitor

Indexed keywords

BORTEZOMIB; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; MONOCLONAL ANTIBODY; PROTEASOME INHIBITOR; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; MOUSE; MYELINATED NERVE; NERVE POTENTIAL; NEUROPROTECTION; NONHUMAN; NONMYELINATED NERVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSORY NEUROPATHY; SPINAL GANGLION; UPREGULATION;

BORTEZOMIB; CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY; CYTOKINES; MICE; NEUROPATHY; PROTEASOME INHIBITOR;

ACTION POTENTIALS; ANIMALS; ANTIBODIES; BORONIC ACIDS; CELLS, CULTURED; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; GANGLIA, SPINAL; GENE EXPRESSION REGULATION; MICE; MOTOR ACTIVITY; NEURAL CONDUCTION; NEUROTOXICITY SYNDROMES; PAIN MEASUREMENT; PAIN THRESHOLD; PROTEASOME INHIBITORS; PYRAZINES; SCIATIC NERVE; SENSORY RECEPTOR CELLS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84892494376     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2013.12.020     Document Type: Article

References (49)

1. Alberti L., Thomachot M.C., Bachelot T., Menetrier-Caux C., Puisieux I., Blay J.Y. IL-6 as an intracrine growth factor for renal carcinoma cell lines. Int. J. Cancer 2004, 111:653-661.
2. Badros A., Goloubeva O., Dalal J.S., Can I., Thompson J., Rapoport A.P., Heyman M., Akpek G., Fenton R.G. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 2007, 110:1042-1049.
3. Broyl A., Corthals S.L., Jongen J.L., van der Holt B., Kuiper R., de Knegt Y., van Duin M., el Jarari L., Bertsch U., Lokhorst H.M., Durie B.G., Goldschmidt H., Sonneveld P. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. 2010, 11:1057-1065.
4. Bruna J., Udina E., Ale A., Vilches J.J., Vynckier A., Monbaliu J., Silverman L., Navarro X. Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice. Exp. Neurol. 2010, 223:599-608.
5. Bruna J., Ale A., Velasco R., Jaramillo J., Navarro X., Udina E. Evaluation of pre-existing neuropathy and bortezomib retreatment as risk factors to develop severe neuropathy in a mouse model. J. Peripher. Nerv. Syst. 2011, 16:199-212.
6. Carozzi V.A., Renn C.L., Bardini M., Fazio G., Chiorazzi A., Meregalli C., Oggioni N., Shanks K., Quartu M., Serra M.P., Sala B., Cavaletti G., Dorsey S.G. Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse. PLoS One 2013, 8:e72995.
7. Casafont I., Berciano M.T., Lafarga M. Bortezomib induces the formation of nuclear poly(A) RNA granules enriched in Sam68 and PABPN1 in sensory ganglia neurons. Neurotox. Res. 2010, 17:167-178.
8. Charles K.A., Kulbe H., Soper R., Escorcio-Correia M., Lawrence T., Schultheis A., Chakravarty P., Thompson R.G., Kollias G., Smyth J.F., Balkwill F.R., Hagemann T. The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J. Clin. Invest. 2009, 119:3011-3023.
9. Chauhan D., Uchiyama H., Akbarali Y., Urashima M., Yamamoto K., Libermann T.A., Anderson K.C. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 1996, 87:1104-1112.
10. Dubovy P. Wallerian degeneration and peripheral nerve conditions for both axonal regeneration and neuropathic pain induction. Ann. Anat. 2011, 193:267-275.
11. Dubovy P., Jancalek R., Klusakova I., Svizenska I., Pejchalova K. Intra- and extraneuronal changes of immunofluorescence staining for TNF-alpha and TNFR1 in the dorsal root ganglia of rat peripheral neuropathic pain models. Cell. Mol. Neurobiol. 2006, 26:1205-1217.
12. Favis R., Sun Y., van de Velde H., Broderick E., Levey L., Meyers M., Mulligan G., Harousseau J.-L., Richardson P.G., Ricci D.S. Genetic variation associated with bortezomib-induced peripheral neuropathy. Pharmacogenet. Genomics 2011, 21:121-129.
13. Figiel I. Pro-inflammatory cytokine TNF-alpha as a neuroprotective agent in the brain. Acta Neurobiol. Exp. (Wars) 2008, 68:526-534.
14. Finch C.E., Laping N.J., Morgan T.E., Nichols N.R., Pasinetti G.M. TGF-beta 1 is an organizer of responses to neurodegeneration. J. Cell. Biochem. 1993, 53:314-322.
15. Fisher R.I., Bernstein S.H., Kahl B.S., Djulbegovic B., Robertson M.J., de Vos S., Epner E., Krishnan A., Leonard J.P., Lonial S., Stadtmauer E.A., O'Connor O.A., Shi H., Boral A.L., Goy A. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J. Clin. Oncol. 2006, 24:4867-4874.
16. Goldberg A.L. Development of proteasome inhibitors as research tools and cancer drugs. J. Cell Biol. 2012, 199:583-588.
17. Gómez N., Cuadras J., Batí M., Navarro X. Histologic assessment of sciatic nerve regeneration following resection and graft or tube repair in the mouse. Restor. Neurol. Neurosci. 1996, 10:187-196.
18. Hideshima T., Chauhan D., Schlossman R., Richardson P., Anderson K.C. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001, 20:4519-4527.
19. Hideshima T., Ikeda H., Chauhan D., Okawa Y., Raje N., Podar K., Mitsiades C., Munshi N.C., Richardson P.G., Carrasco R.D., Anderson K.C. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009, 114:1046-1052.
20. Keller E.T., Ershler W.B. Effect of IL-6 receptor antisense oligodeoxynucleotide on in vitro proliferation of myeloma cells. J. Immunol. 1995, 154:4091-4098.
21. Lee H.K., Shin Y.K., Jung J., Seo S.-Y., Baek S.-Y., Park H.T. Proteasome inhibition suppresses Schwann cell dedifferentiation in vitro and in vivo. Glia 2009, 57:1825-1834.
22. Lee K.-M., Jeon S.-M., Cho H.-J. Tumor necrosis factor receptor 1 induces interleukin-6 upregulation through NF-kappaB in a rat neuropathic pain model. Eur. J. Pain 2009, 13:794-806.
23. Leung L., Cahill C.M. TNF-alpha and neuropathic pain-a review. J. Neuroinflammation 2010, 7:27.
24. Li C., Chen S., Yue P., Deng X., Lonial S., Khuri F.R., Sun S.-Y. Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation. J. Biol. Chem. 2010, 285:16096-16104.
25. Liang B., Gardner D.B., Griswold D.E., Bugelski P.J., Song X.Y. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 2006, 119:296-305.
26. Liang B., Song Z., Wu B., Gardner D., Shealy D., Song X.Y., Wooley P.H. Evaluation of anti-IL-6 monoclonal antibody therapy using murine type II collagen-induced arthritis. J. Inflamm. (Lond.) 2009, 6:10.
27. Mateos M.-V., Hernandez J.M., Hernandez M.T., Gutierrez N.C., Palomera L., Fuertes M., Garcia-Sanchez P., Lahuerta J.J., de la Rubia J., Terol M.-J., Sureda A., Bargay J., Ribas P., Alegre A., de Arriba F., Oriol A., Carrera D., Garcia-Larana J., Garcia-Sanz R., Blade J., Prosper F., Mateo G., Esseltine D.-L., van de Velde H., San Miguel J.F. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica 2008, 93:560-565.
28. Miller R.J., Jung H., Bhangoo S.K., White F.A. Cytokine and chemokine regulation of sensory neuron function. Handb. Exp. Pharmacol. 2009, 417-449.
29. Mincheva-Tasheva S., Soler R.M. NF-kappaB signaling pathways: role in nervous system physiology and pathology. Neuroscientist 2013, 19:175-194.
30. Myers R.R., Shubayev V.I. The ology of neuropathy: an integrative review of the role of neuroinflammation and TNF-alpha axonal transport in neuropathic pain. J. Peripher. Nerv. Syst. 2011, 16:277-286.
31. Myers R.R., Campana W.M., Shubayev V.I. The role of neuroinflammation in neuropathic pain: mechanisms and therapeutic targets. Drug Discov. Today 2006, 11:8-20.
32. Navarro X., Verdu E., Buti M. Comparison of regenerative and reinnervating capabilities of different functional types of nerve fibers. Exp. Neurol. 1994, 129:217-224.
33. Navarro X., Verdu E., Wendelscafer-Crabb G., Kennedy W.R. Innervation of cutaneous structures in the mouse hind paw: a confocal microscopy immunohistochemical study. J. Neurosci. Res. 1995, 41:111-120.
34. Orlowski R.Z., Gercheva L., Williams C., Sutherland H.J., Robak T., Masszi T., Goranova-Marinova V., Dimopoulos M.A., Cavenagh J.D., Spicka I., Maiolino A., Suvorov A., Blade J., Samoilova O.S., Van De Velde H., Bandekar R., Kranenburg B., Xie H., Rossi J.-F. Phase II, randomized, double blind, placebo controlled study comparing siltuximab plus bortezomib versus bortezomib alone in patients with relapsed/refractory multiple myeloma. J. Clin. Oncol. 2012, 30:8018. (ASCO Meeting Abstracts).
35. Palanca A., Casafont I., Berciano M.T., Lafarga M. Proteasome inhibition induces DNA damage and reorganizes nuclear architecture and protein synthesis machinery in sensory ganglion neurons. Cell. Mol. Life Sci. 2013 (in press).
36. Poruchynsky M.S., Sackett D.L., Robey R.W., Ward Y., Annunziata C., Fojo T. Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition. Cell Cycle 2008, 7:940-949.
37. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., Rajkumar S.V., Srkalovic G., Alsina M., Alexanian R., Siegel D., Orlowski R.Z., Kuter D., Limentani S.A., Lee S., Hideshima T., Esseltine D.-L., Kauffman M., Adams J., Schenkein D.P., Anderson K.C. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 2003, 348:2609-2617.
38. Rockwell P., Yuan H.M., Magnusson R., Figueiredo-Pereira M.E. Proteasome inhibition in neuronal cells induces a proinflammatory response manifested by upregulation of cyclooxygenase-2, its accumulation as ubiquitin conjugates, and production of the prostaglandin PGE(2). Arch. Biochem. Biophys. 2000, 374:325-333.
39. San Miguel J.F., Schlag R., Khuageva N.K., Dimopoulos M.A., Shpilberg O., Kropff M., Spicka I., Petrucci M.T., Palumbo A., Samoilova O.S., Dmoszynska A., Abdulkadyrov K.M., Schots R., Jiang B., Mateos M.-V., Anderson K.C., Esseltine D.L., Liu K., Cakana A., van de Velde H., Richardson P.G. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 2008, 359:906-917.
40. Sharma A., Sharma H.S. Monoclonal antibodies as novel neurotherapeutic agents in CNS injury and repair. Int. Rev. Neurobiol. 2012, 102:23-45.
41. Staff N.P., Podratz J.L., Grassner L., Bader M., Paz J., Knight A.M., Loprinzi C.L., Trushina E., Windebank A.J. Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons. Neurotoxicology 2013, 39C:124-131.
42. Verdu E., Vilches J.J., Rodriguez F.J., Ceballos D., Valero A., Navarro X. Physiological and immunohistochemical characterization of cisplatin-induced neuropathy in mice. Muscle Nerve 1999, 22:329-340.
43. Vincent M., Sayre N.L., Graham M.J., Crooke R.M., Shealy D.J., Liscum L. Evaluation of an anti-tumor necrosis factor therapeutic in a mouse model of Niemann-Pick C liver disease. PLoS One 2010, 5:e12941.
44. Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V., Baldwin A.S. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998, 281:1680-1683.
45. Watanabe T., Mitsuhashi M., Sagawa M., Ri M., Suzuki K., Abe M., Ohmachi K., Nakagawa Y., Nakamura S., Chosa M., Iida S., Kizaki M. Phytohemagglutinin-induced IL2 mRNA in whole blood can predict bortezomib-induced peripheral neuropathy for multiple myeloma patients. Blood Cancer J. 2013, 3:e150.
46. Williams G.M. Antitumor necrosis factor-alpha therapy and potential cancer inhibition. Eur. J. Cancer Prev. 2008, 17:169-177.
47. Xiao W.H., Zheng H., Zheng F.Y., Nuydens R., Meert T.F., Bennett G.J. Mitochondrial abnormality in sensory, but not motor, axons in paclitaxel-evoked painful peripheral neuropathy in the rat. Neuroscience 2011, 199:461-469.
48. Yamakawa I., Kojima H., Terashima T., Katagi M., Oi J., Urabe H., Sanada M., Kawai H., Chan L., Yasuda H., Maegawa H., Kimura H. Inactivation of TNF-alpha ameliorates diabetic neuropathy in mice. Am. J. Physiol. Endocrinol. Metab. 2011, 301:E844-E852.
49. Zheng H., Xiao W.H., Bennett G.J. Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy. Exp. Neurol. 2012, 238:225-234.